Cowen Remains Bullish on Galapagos NV (GLPG) After AbbVie (ABBV) Declined to Opt-In for Phase III Development of Filgotinib
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis
September 25, 2015 10:49 AM EDTGalapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibitor Best-in-class efficacy and safety in RA in 24-week Phase 2B studies in 877 patients Phase 3 start in RA expected in early 2016
MECHELEN, Belgium, Sept. 25, 2015 (GLOBE NEWSWIRE) -- Galapagos to hold a conference call open to the public  today at 17.15 CET/11:15 AM EDT CODE: 830162
UK: +44 330 336 6025 USA: +1 719 325 2556 Belgium:... MoreGalapagos to advance filgotinib to Phase 3 in rheumatoid arthritis
September 25, 2015 10:49 AM EDTGalapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibitor Best-in-class efficacy and safety in RA in 24-week Phase 2B studies in 877 patients Phase 3 start in RA expected in early 2016
MECHELEN, Belgium, Sept. 25, 2015 (GLOBE NEWSWIRE) -- Galapagos to hold a conference call open to the public  today at 17.15 CET/11:15 AM EDT CODE: 830162
UK: +44 330 336 6025 USA: +1 719 325 2556 Belgium:... MoreAbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End
September 25, 2015 7:13 AM EDTNORTH CHICAGO, Ill., Sept. 25, 2015 /PRNewswire/ --Â AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.
"We believe ABT-494 has the potential to become a best-in-class therapy for patients," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "In our view, ABT-494 also offers a... More
AbbVie's ABT-494 Meets Primary Endpoint in Two Phase 2 Studies in Rheumatoid Arthritis
September 25, 2015 7:12 AM EDTNORTH CHICAGO, Ill., Sept. 25, 2015 /PRNewswire/ --Â AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors. The clinical... More
